The stock of HCW Biologics Inc (HCWB) has seen a -19.03% decrease in the past week, with a -35.36% drop in the past month, and a -68.34% decrease in the past quarter. The volatility ratio for the week is 17.34%, and the volatility levels for the past 30 days are at 12.45% for HCWB. The simple moving average for the past 20 days is -18.36% for HCWB’s stock, with a -63.71% simple moving average for the past 200 days.
Is It Worth Investing in HCW Biologics Inc (NASDAQ: HCWB) Right Now?
Additionally, the 36-month beta value for HCWB is 0.85. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for HCWB is 0.67M and currently, short sellers hold a 1.03% ratio of that float. The average trading volume of HCWB on May 12, 2025 was 10.05K shares.
HCWB) stock’s latest price update
HCW Biologics Inc (NASDAQ: HCWB)’s stock price has dropped by -13.57 in relation to previous closing price of 7.15. Nevertheless, the company has seen a loss of -19.03% in its stock price over the last five trading days. globenewswire.com reported 2025-04-01 that MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock, par value $0.0001 (“Common Stock”), which will be effective at 12:01 a.m. Eastern Time on April 11, 2025. The Company’s Common Stock will be traded on The Nasdaq Capital Market on a reverse split-adjusted basis beginning on April 11, 2025, under the Company’s existing trading symbol “HCWB.”
HCWB Trading at -40.58% from the 50-Day Moving Average
After a stumble in the market that brought HCWB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.87% of loss for the given period.
Volatility was left at 12.45%, however, over the last 30 days, the volatility rate increased by 17.34%, as shares sank -36.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -59.23% lower at present.
During the last 5 trading sessions, HCWB fell by -19.03%, which changed the moving average for the period of 200-days by -74.25% in comparison to the 20-day moving average, which settled at $7.57. In addition, HCW Biologics Inc saw -65.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HCWB starting from Winer Gary M, who purchase 2,308 shares at the price of $26.00 back on May 08 ’25. After this action, Winer Gary M now owns 2,733 shares of HCW Biologics Inc, valued at $60,008 using the latest closing price.
Wong Hing C, the Chief Executive Officer of HCW Biologics Inc, purchase 92,500 shares at $26.00 during a trade that took place back on May 08 ’25, which means that Wong Hing C is holding 493,857 shares at $2,405,000 based on the most recent closing price.
Stock Fundamentals for HCWB
Current profitability levels for the company are sitting at:
- -11.49 for the present operating margin
- 0.28 for the gross margin
The net margin for HCW Biologics Inc stands at -11.7. The total capital return value is set at -48.51. Equity return is now at value -897.37, with -102.21 for asset returns.
Based on HCW Biologics Inc (HCWB), the company’s capital structure generated 1.98 points at debt to capital in total, while cash flow to debt ratio is standing at -1.04. The debt to equity ratio resting at -2.02. The interest coverage ratio of the stock is -25.45.
Currently, EBITDA for the company is -27.68 million with net debt to EBITDA at -0.33. When we switch over and look at the enterprise to sales, we see a ratio of 6.22. The receivables turnover for the company is 4.41for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.19.
Conclusion
In conclusion, HCW Biologics Inc (HCWB) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
